Literature DB >> 11113377

Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection.

S M Holland1.   

Abstract

Cytokines are increasingly used for the therapy of infections in patient populations with special defects in immunity (chemotherapy, bone marrow transplantation, chronic granulomatous disease). The recognition of multiple defects in the systems of the interferon-gamma (IFN-gamma) receptor, interleukin-12 (IL-12) receptor and IL-12 p40 emphasizes the critical roles that cytokines play in preventing and clearing infection. The cases of patients with partially responsive IFN-gamma receptors (autosomal dominant and partial defects) are ideal candidates for successful cytokine prophylaxis and therapy. Better understanding of the critical elements of the cytokine pathways may show us ways to circumvent these defects with complementary cytokine cascades.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113377     DOI: 10.1016/s1286-4579(00)01314-9

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

1.  Friendly fire: anti-cytokine antibodies elicited by microbes.

Authors:  Luigi D Notarangelo; Steven M Holland
Journal:  Nat Med       Date:  2016-09-07       Impact factor: 53.440

Review 2.  Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity.

Authors:  Jacinta Bustamante; Stéphanie Boisson-Dupuis; Laurent Abel; Jean-Laurent Casanova
Journal:  Semin Immunol       Date:  2014-10-26       Impact factor: 11.130

Review 3.  Laboratory evaluation of the IFN-γ circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease.

Authors:  Ana Esteve-Solé; Ithaisa Sologuren; María Teresa Martínez-Saavedra; Àngela Deyà-Martínez; Carmen Oleaga-Quintas; Rubén Martinez-Barricarte; Andrea Martin-Nalda; Manel Juan; Jean-Laurent Casanova; Carlos Rodriguez-Gallego; Laia Alsina; Jacinta Bustamante
Journal:  Crit Rev Clin Lab Sci       Date:  2018-03-04       Impact factor: 6.250

4.  Gamma interferon receptor defect presenting as recurrent tuberculosis.

Authors:  Balasubramanian Sundaram; Sumanth Amperayani; K Dhanalakshmi; Swathi Padmanaban
Journal:  Indian J Pediatr       Date:  2013-05-17       Impact factor: 1.967

5.  Two patients with complete defects in interferon gamma receptor-dependent signaling.

Authors:  Jeroen G Noordzij; Nico G Hartwig; Frank A W Verreck; Sandra De Bruin-Versteeg; Tjitske De Boer; Jaap T Van Dissel; Ronald De Groot; Tom H M Ottenhoff; Jacques J M Van Dongen
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.317

6.  IL-12Rβ1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey.

Authors:  Stéphanie Boisson-Dupuis; Jamila El Baghdadi; Nima Parvaneh; Aziz Bousfiha; Jacinta Bustamante; Jacqueline Feinberg; Arina Samarina; Audrey V Grant; Lucile Janniere; Naima El Hafidi; Amal Hassani; Daniel Nolan; Jilali Najib; Yildiz Camcioglu; Nevin Hatipoglu; Cigdem Aydogmus; Gonul Tanir; Caner Aytekin; Melike Keser; Ayper Somer; Guside Aksu; Necil Kutukculer; Davood Mansouri; Alireza Mahdaviani; Setareh Mamishi; Alexandre Alcais; Laurent Abel; Jean-Laurent Casanova
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

7.  Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series.

Authors:  Seyed Alireza Mahdaviani; Mazdak Fallahi; Mahnaz Jamee; Majid Marjani; Payam Tabarsi; Afshin Moniri; Parisa Farnia; Zahra Daneshmandi; Nima Parvaneh; Jean-Laurent Casanova; Jacinta Bustamante; Davood Mansouri; Ali Akbar Velayati
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-03-01       Impact factor: 3.944

8.  Transient Decrease of Circulating and Tissular Dendritic Cells in Patients With Mycobacterial Disease and With Partial Dominant IFNγR1 Deficiency.

Authors:  Laura Dotta; Donatella Vairo; Mauro Giacomelli; Daniele Moratto; Nicola Tamassia; William Vermi; Silvia Lonardi; Jean-Laurent Casanova; Jacinta Bustamante; Silvia Giliani; Raffaele Badolato
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.